Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

From Playing It Safe To All-In: Genentech Takes Risks With Oncology Pipeline

Executive Summary

Compared to its old oncology R&D lineup, Genentech's current cancer pipeline makes it clear that the company is embracing a new, riskier development strategy
Advertisement

Related Content

With A Novel Pipeline, Pfizer Tries A New Oncology Business Unit Too
Highlights Of The American Society Of Clinical Oncology, In Brief
AVADO Presented At ASCO; But After The Fanfare, What Does It Signify?
Genentech Continues Pipeline Push After Rituxan Fizzles In PPMS
Next For Genentech: Tackling Neuroscience And Infectious Disease
Roche Mantra Is “Pipeline, Pipeline, Pipeline;” R&D Surge Continues In 2008
Avastin Growth Not Limited To Breast Cancer In 2008, Genentech Says
GSK Tykerb Priced At Discount To Herceptin In Metastatic Breast Cancer
Roche Keeps Lifecycle Management In Motion For Oncology Portfolio
Roche Keeps Lifecycle Management In Motion For Oncology Portfolio
Advertisement
UsernamePublicRestriction

Register

PS049750

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel